|
Friday, 12 March 2010 17:27 |
 Affymax, Inc. (Nasdaq: AFFY - News) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize Hematide™, Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients. |
|
Read more...
|
|
Friday, 12 March 2010 12:14 |
|
 Novartis (NOVN.VX) has taken an exclusive option to develop Transgene's (TRNG.PA) cancer vaccine TG4010, but the deal fell short of investors' hopes, pulling the shares in the French biotechnology company down 12 percent.
|
|
Read more...
|
|
Thursday, 11 March 2010 15:51 |
 Merck & Co., Inc. (NYSE: MRK - News): Sanofi-aventis (EURONEXT: SAN) (NYSE: SNY - News) and Merck & Co., Inc. (NYSE: MRK - News) announced today that sanofi-aventis has exercised its option to combine Merial with Intervet/Schering-Plough, Merck’s Animal Health business, to create a global leader in Animal Health. |
|
Read more...
|
|
Wednesday, 10 March 2010 16:16 |
|
 MabCure, Inc. (OTCBB:MBCI) (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. |
|
Read more...
|
|
Wednesday, 10 March 2010 14:11 |
|
 Orthofix International N.V. (NASDAQ: OFIX) (the Company) announced today it has sold the assets of its vascular business, including its AV-Impulse® mechanical compression technology, to Covidien. |
|
Read more...
|
|
Tuesday, 09 March 2010 13:06 |
 Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing under NASDAQ Listing Rule 5550(a)(2). |
|
Read more...
|
|
Monday, 08 March 2010 16:46 |
|
 YM BioSciences Inc. , today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit. Each unit consists of one common share and one half of one common share purchase warrant.
|
|
Read more...
|
|
Monday, 08 March 2010 16:40 |
 Astellas Pharma Inc. needs to increase its $3.5 billion hostile takeover bid for OSI Pharmaceuticals Inc. by 15 percent, said OrbiMed Advisors LLC, OSI’s fifth-biggest shareholder. |
|
Read more...
|
|
Saturday, 06 March 2010 13:06 |
|
 Repligen Corporation announced today that it has acquired the assets of BioFlash Partners, LLC, (BioFlash) including a technology platform for the production of pre-packed, "plug and play" chromatography columns. This patented technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins.
|
|
Read more...
|
|
Friday, 05 March 2010 15:51 |
 NicOx S.A. (NYSE Euronext Paris: COX) and Bausch + Lomb, a leading eye health company, today announced the companies have entered into a licensing agreement which grants Bausch + Lomb exclusive worldwide rights to develop and commercialize NCX 116 (previously PF-03187207), a nitric oxide-donating prostaglandin F2-alpha analog. |
|
Read more...
|
|
|
Friday, 12 March 2010 16:25 |
 Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company. |
|
Read more...
|
|
Thursday, 11 March 2010 17:56 |
 BT Pharma, a biopharmaceutical company developing innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today that it has raised EUR 13.1 million in additional funding and changed its name to Genticel. |
|
Read more...
|
|
Thursday, 11 March 2010 12:43 |
|
 Abbott (NYSE:ABT - News) and Facet Biotech Corporation (Nasdaq:FACT - News) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. Abbott will acquire Facet for $27 per share in cash for a net transaction value of approximately $450 million, which includes a purchase price of approximately $722 million less Facet's projected cash and marketable securities at closing of approximately $272 million.
|
|
Read more...
|
|
Wednesday, 10 March 2010 15:13 |
|
 Sigma-Aldrich will be offering a suite of knockout rat models designed to facilitate more predictive ADME/Tox studies. The four new models were developed by Sigma Advanced Genetic Engineering Labs (SAGE™) and have single gene deletions to well-established drug transporters Mdr1a, Mrp1, Mrp2, Pxr, and Bcrp.
|
|
Read more...
|
|
Tuesday, 09 March 2010 14:08 |
 Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it completed its previously announced registered direct offering to institutional investors. The final offering of 6.7 million shares of common stock priced at $2.72 per share along with warrants to purchase approximately 2.3 million shares of its common stock was led by Venrock and resulted in gross proceeds of $18.2 million and net proceeds, after deducting the placement agents' fees and offering expenses, of approximately $16.8 million. |
|
Read more...
|
User Rating :   / 1
|
Tuesday, 09 March 2010 12:01 |
 Dow AgroSciences, a growing and thriving life sciences company, announces plans for a multi-year expansion of its global headquarters in northwest Indianapolis, with investment of more than $340 million and the addition of more than 550 scientific and commercial jobs over the next five years. |
|
Read more...
|
|
Monday, 08 March 2010 16:43 |
 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Finnzymes. The business is a well-recognized provider of integrated tools for high-performance polymerase chain reaction (PCR), including reagents, instruments, consumables and kits that make the PCR process faster and more accurate for applications including basic genomic research, genetic testing, forensics and food safety. |
|
Read more...
|
|
Saturday, 06 March 2010 16:11 |
|
Gamma Pharmaceuticals, Inc. (PINKSHEETS: GMPM): Gamma Pharmaceuticals, Inc. ("Gamma" or the "Company") announced that it has entered into a multi-year agreement (the "Agreement") with one of North America's leading wholesale distribution organizations to distribute the full line of Gamma products. |
|
Read more...
|
|
Saturday, 06 March 2010 12:57 |
 Transition Therapeutics Inc. (TSX:TTH - News) (Nasdaq:TTHI - News) today announced that it has acquired the rights to a series of preclinical compounds from Eli Lilly and Company in the area of diabetes. Under the licensing and collaboration agreement, Transition will receive exclusive worldwide rights to develop and potentially commercialize a class of compounds that, in preclinical diabetes models showed potential to provide glycemic control and other beneficial effects including weight loss. |
|
Read more...
|
|
Friday, 05 March 2010 14:49 |
|
 Pfizer Inc (PFE.N) is set to make a near $4 billion offer for German generic drug maker Ratiopharm GmbH this week, competing with bids from Teva Pharmaceutical Industries Ltd (TEVA.TA) and Actavis, several sources familiar with the situation said.
|
|
Read more...
|
|
